Category - Developments

Developments

Hepion Pharma partners with University of Alberta’s Applied Pharmaceutical Innovation

Hepion Pharmaceuticals (NASDAQ:HEPA) has partnered with Applied Pharmaceutical Innovation (API) to expand its research capabilities and further characterize its lead candidate, CRV431. API is an independent institute...

July 31, 2019

Developments

FDA clears Hepion Pharma’s IND for CRV431 for the treatment of NASH

The FDA has authorized Hepion Pharmaceuticals (NASDAQ:HEPA) to proceed with its IND opening study of CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “Based on the preclinical and clinical studies we’ve...

July 29, 2019

Developments

Zenabis increases licensed capacity by more than 40% with substantial completion of Zenabis Atholville

Zenabis Global (TSX:ZENA) announced the licensing of Phase 2C – Part 1 at its Zenabis Atholville facility, adding an additional 9,800 kg of licensed annual cultivation capacity of cannabis. This licensing increases...

July 29, 2019

Developments

Theralase enrols first patient in Phase 2 NMIBC clinical study

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) enrolled the first patient in a Phase 2 clinical study of its light activated photodynamic compounds (PDC) in patients with non-muscle invasive bladder cancer (NMIBC) who...

July 29, 2019

Developments

Aeglea BioTherapeutics gets FDA breakthrough designation for pegzilarginase

Aeglea BioTherapeutics’ (NASDAQ:AGLE) pegzilarginase received FDA breakthrough therapy designation for the treatment of arginase 1 deficiency (ARG1-D). ARG1-D is a rare genetic childhood disease that causes severe...

July 25, 2019

Developments

Proteostasis doses first patient in Phase 2 cystic fibrosis trial

Proteostasis Therapeutics (NASDAQ: PTI) dosed the first patient in a 28-day Phase 2 trial evaluating combinations of PTI-801, PTI-808 and PTI-428 for the treatment of cystic fibrosis (CF). CF is caused by a mutation in...

July 25, 2019

Developments

Matinas gets FDA fast track, QIDP designations for MAT2203

The FDA granted fast track and qualified infectious disease product (QIDP) designations to Matinas BioPharma’s (NYSE AMER:MTNB) MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is a lipid nano-crystal...

July 25, 2019

Developments

Abeona reports positive interim data from Phase 1/2 gene therapy trial

Abeona Therapeutics (NASDAQ:ABEO) reported positive data from its ongoing Phase 1/2 clinical trial of ABO-102 for the treatment of Sanfilippo syndrome type A (MPS IIIA). Primarily affecting the central nervous system...

July 25, 2019

Developments

XPhyto receives German cannabis license for scientific cultivation and extraction

The German Federal Institute for Drugs and Medical Devices (BfArM) granted XPhyto Therapeutics’ German subsidiary, Bunker Pflanzenextrakte, a cannabis cultivation and extraction license for scientific purposes. Subject...

July 25, 2019

Developments

DelMar Pharma enrolls first patient in adjuvant arm of Phase 2 glioblastoma trial

DelMar Pharmaceuticals (NASDAQ:DMPI) treated the first MGMT-unmethylated glioblastoma multiforme (GBM) patient in the adjuvant trial arm of its Phase 2 study of VAL-083. This study arm will enroll up to 24 newly...

July 24, 2019

Category - Developments

Hepion Pharma partners with University of Alberta’s Applied Pharmaceutical Innovation

FDA clears Hepion Pharma’s IND for CRV431 for the treatment of NASH

Zenabis increases licensed capacity by more than 40% with substantial completion of Zenabis Atholville

Theralase enrols first patient in Phase 2 NMIBC clinical study

Aeglea BioTherapeutics gets FDA breakthrough designation for pegzilarginase

Proteostasis doses first patient in Phase 2 cystic fibrosis trial

Matinas gets FDA fast track, QIDP designations for MAT2203

Abeona reports positive interim data from Phase 1/2 gene therapy trial

XPhyto receives German cannabis license for scientific cultivation and extraction

DelMar Pharma enrolls first patient in adjuvant arm of Phase 2 glioblastoma trial

General

More